BioCentury
ARTICLE | Company News

Novartis withdraws Tasigna application

July 1, 2014 1:30 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) withdrew a European application to expand the label of Tasigna nilotinib to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in whom treatment with the company's Gleevec imatinib has not led to a complete molecular response. Tasigna is already approved in Europe for second-line treatment of chronic and accelerated phase Ph+ CML, including patients who are resistant to imatinib. The BCR-ABL tyrosine kinase inhibitor is also approved to treat newly diagnosed Ph+ CML in chronic phase. ...